Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 4Phase 1/2 2Phase 2/3 1

Status

Completed 4Unknown 1

Sponsor Class

OTHER 5NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 5

Conditions

Melanoma 5Uveal Melanoma 2Skin Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Eye Neoplasms 1

Interventions

Cisplatin 1041Cyclophosphamide 973Carboplatin 954Radiotherapy 893Bevacizumab 847Gemcitabine 817pembrolizumab 759Paclitaxel 738Docetaxel 734Oxaliplatin 706Capecitabine 649Fluorouracil 564Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 402Leucovorin 377Cytarabine 342Cetuximab 340Lenalidomide 326Trastuzumab 323Pemetrexed 315durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 278Temozolomide 275Prednisone 274

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × OTHER × MAGEA3 protein, human × Clear all
NCT00960752 2021-08-13

Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist

M.D. Anderson Cancer Center

Phase 2 Completed
47 enrolled 9 charts
Dermatologic

Melanoma, Neoplasm Metastasis, Neoplasms

NCT01266603 2020-02-19

High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI

M.D. Anderson Cancer Center

Phase 2 Completed
44 enrolled 11 charts
Dermatologic

Melanoma

NCT00254397 2019-10-16

Melanoma Vaccine With Peptides and Leuprolide

M.D. Anderson Cancer Center

Phase 2 Completed
98 enrolled 11 charts
Dermatologic

Uveal Melanoma, Eye Neoplasms, Melanoma, Skin Neoplasms

NCT00085189 2014-05-22

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

University of Southern California

Phase 2 Completed
42 enrolled
Dermatologic

Uveal Melanoma, Melanoma

NCT00153569 2010-05-26

Multiepitope Peptide Vaccination in Melanoma

Charite University, Berlin, Germany

Phase 2 Unknown
25 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡